Belinostat (BELEODAQ)

At CrCl 30 to less than 60 mL/min, give 500 mg/m2 by IV infusion over 30 minutes once daily on days 1 through 5 of each 21-day cycle. Avoid use below CrCl 30. No adjustment is recommended at CrCl 60 to less than 90. The usual unadjusted regimen is 1,000 mg/m2 on the same schedule. These renal instructions do not replace UGT1A1, hepatic, interaction, or treatment-emergent toxicity modifications.

Section 2.4 specifies 500 mg/m2 IV over 30 minutes once daily on days 1-5 of a 21-day cycle for CrCl 30 to below 60 mL/min. Avoid below 30; no adjustment for 60 to below 90. The current mirror's selected renal wording agrees.

Section 2.6 separately matters: when the starting dose is already 500 mg/m2 and a UGT1A1 inhibitor cannot be avoided, the table directs interruption during inhibitor use and resumption after five inhibitor half-lives, rather than another simple percentage reduction. Review hepatic, genotype and toxicity modifications separately.

This RX List version reports no exposure change with creatinine clearance above 39 mL/min and insufficient data to recommend a dose at CrCl 39 mL/min or lower. This is a limitation of this source version, not a finding that no renal adjustment is needed.

The currently retrieved mirror specifies 500 mg/m2 IV over 30 minutes daily on days 1-5 of each 21-day cycle at CrCl 30 to below 60 mL/min. Avoid below 30; no adjustment at 60 to below 90.

This differs from the retained earlier mirror summary that lacked a regimen at CrCl 39 or lower. It now agrees with the selected official renal section. This is reconciliation of the retrieved renal wording, not independent approval of the entire monograph or removal of other dose-modification requirements.